{"id":"regorafenib-and-dibiri","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1946170","moleculeType":"Small molecule","molecularWeight":"482.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regorafenib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, KIT, RET, RAF) involved in tumor angiogenesis and proliferation. DIBIRI is a nanoparticle-bound formulation of irinotecan designed to improve tumor accumulation and reduce systemic toxicity. The combination leverages anti-angiogenic and cytotoxic mechanisms to target colorectal cancer.","oneSentence":"Regorafenib is a multi-kinase inhibitor that blocks tumor angiogenesis and growth signaling, while DIBIRI (dinitro-irinotecan) is a lipophilic prodrug of irinotecan that enhances drug delivery to tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:43.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT05794971","phase":"PHASE3","title":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-10","conditions":"Colorectal Cancer Liver Metastases, Regorafenib","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Drug: Irinotecan","Procedure: TACE","Device: drug eluting-bead"],"phase":"phase_3","status":"active","brandName":"Regorafenib and DIBIRI","genericName":"Regorafenib and DIBIRI","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regorafenib is a multi-kinase inhibitor that blocks tumor angiogenesis and growth signaling, while DIBIRI (dinitro-irinotecan) is a lipophilic prodrug of irinotecan that enhances drug delivery to tumors. Used for Metastatic colorectal cancer (Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}